CANCTema Oncology ETF
Seeks to provide long-term growth.
By Tema ETFs · Launched 2023
Annual Cost
0.75%
#4,069 of 6,040 · expensive
Fund Size
$211M
#2,409 of 6,040 · mid-size
Return (1Y)
+54.7%
Track Record
3 years
#3,045 of 6,040 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$15,407+54.1%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundHoldings
By weightConcentration
Top 10 holdings = 43.8% of fundmoderately concentrated
Revolution Medicines Inc
6.3%
Novartis AG
5.0%
Bridgebio Pharma Inc
4.8%
AstraZeneca PLC
4.6%
Eli Lilly & Co
4.3%
Bristol-Myers Squibb Co
4.2%
Roche Holding AG
4.1%
Merck & Co Inc
3.8%
Arcellx Inc
3.4%
Cogent Biosciences Inc
3.3%
Asset allocation
Stocks
100.5%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
22.9%High
Year-on-year price swings
Max drawdown
-28.0%Moderate
Worst peak-to-trough loss
Sharpe (3Y)
0.77Decent risk-adjusted returns
Sortino (3Y)
1.13Good downside protection
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks to provide long-term growth.
- Strategy
- Invests primarily in publicly listed companies that derive at least 50% of revenues from oncology, focusing on large pharmaceutical firms, diagnostic businesses, and healthcare service providers. Targets companies with a market capitalization of at least $100 million, with significant investments expected in the U.S. and Europe.
- Inception date
- August 14, 2023
- Fund family
- Tema ETFs
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save CANC to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18